Tinnitus, Misophonia, Hyperacusis: Otoactive Compounds & Targets

A new computational analysis of nearly 8,000 research abstracts has systematically mapped the chemical universe of drugs that can damage or protect the inner ear. The study, led by researchers Aylin del Moral-Morales, Jean Arguello-Camarillo, and Jesús Yael Castañón Bello, identified 1,758 such “otoactive” compounds, creating the largest public registry of its kind. Their work pinpoints key biological targets for ototoxic drugs and provides a new tool for developing protective strategies.

How AI Mapped Thousands of Otoactive Compounds

The researchers faced a substantial challenge: the scientific literature on drug-induced hearing damage is vast, fragmented, and growing rapidly. Manually reviewing it would be impractical. To solve this, they built an automated Python pipeline. It started by retrieving 7,801 relevant abstracts from PubMed. They then used OpenAI’s GPT-4 as a precise text extraction tool, training it to identify compound names and their explicitly stated roles—whether a drug was reported as ototoxic (hearing-damaging) or otoprotective (hearing-protecting).

This list of named compounds was then enriched with chemical structure data from PubChem. Finally, the team cross-referenced the compounds with BindingDB, a database of measured drug-protein interactions. This final step allowed them to move beyond a simple list and construct a detailed biological network, showing which human proteins each otoactive drug interacts with.

A Registry of 1,758 Drugs Affecting Hearing

The pipeline’s output is a clear and organized dataset. From the thousands of abstracts, the model identified 1,758 unique small molecules with a documented effect on the auditory system. The breakdown is critical: 1,092 were flagged as ototoxic, while 619 were identified as otoprotective. Some compounds, like certain antioxidants, may appear in both categories depending on the context.

Well-known offenders like the antibiotic class aminoglycosides and the chemotherapy agent cisplatin were confirmed. But the registry expands the list far beyond these classic examples, including many other drugs where hearing effects may be a lesser-known side effect or a potential area for therapeutic intervention.

ABCC3, ABCC4, and Albumin Emerge as Key Hubs

By analyzing the network of drug-protein interactions, the study moved from a catalog to a mechanistic insight. The data highlighted three proteins as major hubs for interactions with ototoxic compounds: the transporters ABCC3 and ABCC4, and the blood protein albumin.

This finding is significant. ABCC3 and ABCC4 are known to move drugs and other molecules out of cells. Their central role suggests they may be crucial in either concentrating toxins inside hair cells of the inner ear or in failing to remove them. Albumin, the most abundant protein in blood, binds to many drugs in the bloodstream. Its prominence in the network indicates that how a drug is transported in the body heavily influences its potential to reach and damage the inner ear. These hubs represent promising targets for future protective strategies that could intercept toxins before they cause harm.

Practical Implications for Patients and Clinicians

The most immediate product of this research is the public web application, OtotoxDB. This tool allows researchers and clinicians to search the registry, explore drug-target networks, and download the data. For a scientist screening for new otoprotective drugs, it provides a starting point. For an audiologist or oncologist, it offers a searchable evidence base to understand the auditory risks of specific medications.

This work also establishes a framework for ongoing surveillance. As new papers are published, the automated pipeline can update the registry, ensuring it remains current. This is vital for keeping pace with newly developed pharmaceuticals. Furthermore, by clearly distinguishing ototoxic from otoprotective compounds, the research directly aids the development of new treatments for hearing disorders. Identifying drugs with protective properties opens avenues for repurposing or designing novel therapies to shield hearing during necessary but risky treatments like chemotherapy.

The study underscores that hearing health is often connected to broader medical treatment. Just as baseline mental health can influence treatment outcomes for insomnia, a patient’s existing hearing status or genetic predisposition to ototoxicity should be considered in treatment planning. A systematic, evidence-based map of drug risks is a foundational step toward more personalized and protective care.

The research discussed here, “A computational pipeline to characterize the chemical and biological landscape of otoactive small-molecules,” is published in Frontiers in Drug Discovery and is available via its DOI: 10.3389/fddsv.2026.1834905.